Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the “Company”) on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS and the fully committed private placement. 

The Company’s board of directors (the “Board”) hereby calls for an extraordinary general meeting on 9 January 2025 at 09:00 CET (the “EGM”) to resolve upon the matters proposed by the Board in the attached EGM notice. 

The EGM will be held electronically. For participation, please log in at https://dnb.lumiagm.com/ with the user ID and password provided. 

All documents and appendices regarding the EGM are made available at the Company’s website: www.ultimovacs.com.

For further information, please see www.ultimovacs.com or contact:

Hans Vassgård Eid, Interim CEO and CFO, Ultimovacs ASA 
Email: [email protected] 
Phone: +47 482 48632

Attachments

• Appendix 1 – Registration and proxy form to the Extraordinary General Meeting
• Appendix 3 – Draft Articles of Association
• Appendix 2 – List of shareholders in Zelluna
• Appendix 4 – Biographies for proposed Board
• Appendix 5 – Pre-committing investors in the Private Placement